Published: 4 days ago

Wellford Clinics joins new Cannabis Based Medicines Association (CBMA) to increase patient access to medical cannabis and promote best practice across sector 

 

  • Wellford Clinics is a founding member of the Cannabis Based Medicines Association (CBMA), a new industry body representing medical cannabis clinics and manufacturers 
  • The CBMA’s work is built around three pillars: putting patient safety first, strengthening the clinical evidence base for medical cannabis, and raising industry standards. 

 

London, UK (10 November 2026) – Wellford Clinics has become a founding member of the Cannabis Based Medicines Association (CBMA), a new UK body focused on increasing patient access to medical cannabis and promoting best practice across the sector.  

Unlike broader cannabis industry bodies, the CBMA is dedicated exclusively to cannabis-based medicines, with voting rights reserved for licensed UK operators. The Association’s work is built around three priorities: putting patient safety first, strengthening the clinical evidence base for prescribing medical cannabis, and raising standards across the industry. 

Putting patients first and strengthening the evidence

In common with all CBMA members, Wellford Clinics has committed to prioritising patients and never placing commercial gain ahead of patient safety and wellbeing.  

Wellford Clinics will contribute clinical expertise and patient insights to support the development of real-world evidence and the systematic collection of patient-reported outcome measures (PROMs) to further improve understanding of medical cannabis treatment outcomes. 

Working together to raise industry standards

Wellford Clinics will also work with other CBMA members to devise a new code of conduct setting new industry benchmarks for medical cannabis cultivation, production, prescribing and promotion.   

Richard Guest, Chief Commercial Officer, Wellford Holdings, said: “Patient safety must be at the heart of everything the medical cannabis sector does. As the industry continues to grow, it is important that providers, manufacturers and regulators work together to support consistently high standards of clinical care, governance and evidence generation. We’re proud to be a founding member of the CBMA and to help support an organisation focused on promoting best practice across the sector.  

“Patients deserve confidence that medical cannabis is prescribed appropriately, monitored carefully and backed by robust clinical practices. At Wellford Clinics, we already operate to high standards of clinical oversight and patient care. Through the CBMA, we look forward to contributing our expertise and working with other responsible organisations to strengthen standards across the industry.” 

Ludovic Rachou, CEO of the CBMA, said: “Medical cannabis has an important role to play in healthcare, but the industry must earn the confidence of patients, clinicians and regulators. 

“The CBMA brings responsible businesses together to raise standards, strengthen accountability and work constructively with those responsible for patient care. What sets the CBMA apart is that it is led by licensed UK operators and puts patients first. We will work with clinics to build the evidence that patients, prescribers and regulators need. We want to help establish cannabis-based medicines as a trusted part of mainstream healthcare.” 

To mark the launch, the CBMA has published a founding manifesto Towards mainstream healthcare: Better access, higher standards, a responsible industry. The manifesto sets out priorities for improving patient access, strengthening standards and supporting proportionate regulation. 

Notes to Editors 

About Wellford Clinics 

Wellford Clinics is a UK-based medical cannabis provider dedicated to improving patient outcomes through access to high-quality, clinically led treatment options. Through a vertically integrated model spanning cultivation, production and patient care, Wellford Clinics is committed to maintaining high standards of quality, consistency and oversight across every stage of the medical cannabis journey, from plant to patient, to provide patients and healthcare professionals with greater confidence in the quality of medical cannabis treatment.  

Through its UK specialist clinic services, Wellford Clinics supports eligible patients living with a range of chronic and complex health conditions, offering personalised treatment plans overseen by experienced clinicians.  

For more information, visit: https://wellfordclinics.com/    

About the CBMA 

The Cannabis-Based Medicines Association represents businesses involved in cannabis-based medicines, promoting responsible industry conduct, higher standards and appropriate patient access. It is the first trade association dedicated to medical cannabis in the UK, and voting rights are reserved for licensed UK operators. Founding members include Curaleaf, Glass Pharms and Wellford. 

Media contacts: 

Ray Dunne 

Head of Communications, Wellford Clinics 

[email protected]  

Press office  

[email protected]